PubRank

Youngchul Song

Author PubWeight™ 82.10‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007 32.68
2 Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008 14.47
3 Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010 7.78
4 Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008 4.95
5 Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A 2009 4.02
6 Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2012 3.39
7 BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov 2011 3.34
8 Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest 2011 2.20
9 An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 2010 2.14
10 MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res 2012 1.87
11 PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Proc Natl Acad Sci U S A 2013 1.57
12 Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res 2013 1.52
13 Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res 2012 1.45
14 mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discov 2013 1.21
15 Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proc Natl Acad Sci U S A 2012 1.09
16 Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer. Cancer Res 2011 0.98
17 Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. Clin Cancer Res 2013 0.97